ABBV · News · 20260909N
Product / Drug Pipeline Progress
AbbVie Inc. · 2026-09-09 · Importance 29 · Surprise 30 · In source text
AbbVie identified continued growth of its SKYRIZI and RINVOQ immunology franchises as core commercial drivers. The company expects additional growth from new indications for these immunology medicines. AbbVie also highlighted an expanding oncology and neuroscience pipeline, including plans for a rapid regulatory filing for the cancer therapy etentamig.
Key facts
- AbbVie anticipates a rapid regulatory filing for its cancer therapy etentamig. source
- AbbVie executives presented their growth strategy at a Wells Fargo conference focusing on the continued success of their SKYRIZI and RINVOQ immunology franchises and an expanding pipeline in oncology and neuroscience. source
- The company expects significant growth drivers from new indications for its key immunology drugs. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | AbbVie anticipates a rapid regulatory filing for its cancer therapy etentamig. |